Eli Lilly and Company $LLY Holdings Lifted by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 7.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 68,978 shares of the company’s stock after acquiring an additional 4,774 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $52,630,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. OneAscent Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 32.0% during the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock valued at $280,000 after buying an additional 87 shares in the last quarter. Sax Wealth Advisors LLC raised its position in Eli Lilly and Company by 14.3% during the second quarter. Sax Wealth Advisors LLC now owns 689 shares of the company’s stock valued at $537,000 after buying an additional 86 shares during the period. Finally, Lattice Capital Management LLC raised its position in Eli Lilly and Company by 19.6% during the second quarter. Lattice Capital Management LLC now owns 1,218 shares of the company’s stock valued at $949,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 7.8%

Shares of LLY stock opened at $1,020.39 on Friday. The stock’s 50 day simple moving average is $1,052.61 and its 200 day simple moving average is $896.17. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $964.66 billion, a price-to-earnings ratio of 44.46, a PEG ratio of 0.82 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the business earned $5.32 earnings per share. The company’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a report on Monday, November 10th. Cantor Fitzgerald increased their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft increased their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,201.17.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat + bullish 2026 guidance — Lilly reported stronger‑than‑expected Q4 revenue and EPS and guided FY‑2026 revenue and EPS above consensus, a primary driver of the recent rally. Eli Lilly shares soar after Q4 beat
• Positive Sentiment: Morgan Stanley raised its price target to $1,313, signaling increased analyst confidence and additional upside in the stock. Price Target Raised to $1,313.00 at Morgan Stanley
• Positive Sentiment: JPMorgan raised its price target to $1,300 and kept an overweight rating — another endorsement that likely supported buying. Price Target Raised to $1,300.00 at JPMorgan Chase & Co.
• Positive Sentiment: Cantor Fitzgerald lifted its target to $1,205 and cited easing GLP‑1 pricing fears thanks to Lilly’s outlook, reinforcing the bullish narrative. Price Target Raised to $1,205.00 at Cantor Fitzgerald
• Positive Sentiment: Capacity investment — Lilly announced a ~$3.5B manufacturing facility in Pennsylvania to expand production, supporting the company’s ability to meet rising GLP‑1 demand. Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Brokerage consensus remains constructive — brokerages give LLY a “moderate buy” consensus, which supports the longer‑term case but may limit near‑term surprise potential. Given Consensus Rating of “Moderate Buy”
• Neutral Sentiment: Minor institutional repositioning — Alecta reportedly trimmed its Lilly stake; typical portfolio rotations can add volume but are not a major directional force alone. Alecta Trims Eli Lilly Stake
• Negative Sentiment: Low‑cost competitor noise — Hims & Hers announced a $49 compounded oral GLP‑1 offering, which sparked a selloff amid concerns about pricing pressure and the durability of branded margins. That announcement caused a sharp intraday pullback. Novo and Eli fall after Hims & Hers announce $49 copy
• Negative Sentiment: Investor/legal probes — Two investor alerts (Scott+Scott and Kahn Swick) are investigating Lilly’s directors/officers and a proposed Ventyx transaction; these raise governance/transaction risk and can increase short‑term volatility. Scott+Scott Investor Alert Kahn Swick Ventyx Alert

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.